BOCA RATON, Fla., April 17 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals will announce first quarter 2006 financial results on Wednesday, April 26, 2006, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET.
The live webcast can be accessed at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=100445&eventID=1300154 or via the Nabi Biopharmaceuticals website at http://www.nabi.com . If you do not have Internet access, the U.S./Canada call-in number is 800-798-2864 conference code 92481183, and the international call-in number is 617-614-6206 conference code 92481183. An audio replay will be available for U.S./Canada callers at 888-286-8010 conference code 31267148, and for international callers at 617-801-6888 conference code 31267148.
An archived version of the webcast will be available at the same Internet address through May 3, 2006. The audio replay will also be available through May 3, 2006. The press release will be available on the company's website at http://www.nabi.com .
UBS Global Specialty Pharmaceuticals Conference
Dr. Henrik Rasmussen, Senior Vice President, Clinical, Medical and Regulatory Affairs, will be presenting at the 2006 UBS Global Specialty Pharmaceuticals Conference on April 24, 2006 at 4:00 ET at the Grand Hyatt Hotel, Park Avenue at Grand Central Terminal, New York, New York. Dr. Rasmussen will be providing a corporate overview and a review of the Gram- positive program.
Dr. Rasmussen's presentation will be webcast live at: http://event.streamx.us/event/20060424 or can be accessed through our website at http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol-calendar .
The webcast presentation will be available through May 24, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis and transplant, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at: http://www.nabi.com .
Audio: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1300154http://event.streamx.us/event/20060424Nabi BiopharmaceuticalsCONTACT: Thomas E. Rathjen, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800
